The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
申请人:Imperial College Of Science,
Technology And Medicine
公开号:EP3694866A1
公开(公告)日:2020-08-19
US9693997B2
申请人:——
公开号:US9693997B2
公开(公告)日:2017-07-04
[EN] MAP4K4 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K4
申请人:IMPERIAL INNOVATIONS LTD
公开号:WO2019073253A1
公开(公告)日:2019-04-18
This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).